Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease

NCT07281456 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

NIH

Sponsor class

Conditions

Sjogren's Syndrome

Interventions

DRUG: Tofacitinib

Sponsor

National Institute of Dental and Craniofacial Research (NIDCR)